Helens HK$2.51 billion IPO
We advised the underwriter on the IPO and HKEX listing
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Kindstar Globalgene Technology HK$2.21 billion IPO
We advised Kindstar Global on its IPO and HKEX listing
Zylox-Tonbridge Medical Technology HK$2.56 billion IPO
We advised Zylox-Tonbridge Medical Technology on its IPO and HKEX listing
Nayuki Holdings HK$5.1 billion IPO
We advised Nayuki Holdings on its IPO and HKEX listing
CARsgen Therapeutics HK$3.1 billion IPO
We advised CARsgen Therapeutics on its IPO and HKEX listing
Bairong HK$3.76 billion IPO
We advised the underwriters on the IPO and HKEX listing
New Horizon Health HK$2.04 billion IPO
We advised New Horizon Health on its IPO and HKEX listing
Akeso HK$1.19 billion share placement
We advised the placing agent in the placement of new shares
Ocumension Therapeutics HK$793.8 million top-up placement of shares
We advised the placing agent in connection with the equity offering
RemeGen HK$4 billion Hong Kong IPO
Davis Polk advised the underwriters in the initial public offering of RemeGen Co., Ltd. on the Hong Kong Stock Exchange and an international offering and listing in reliance on Rule 144A…